Zelsuvmi Q4 Revenue Reaches $9.1M
Reports Q4 Zelsuvmi revenue $9.1M vs. $7.1M vs. last year. CEO Scott Plesha commented, "We are delighted with the growth of Zelsuvmi in our second quarter of commercialization despite the seasonal reduction of patients seeking MC treatment during Q4. The launch metrics, including prescriptions, revenue growth, gross to net discounts and other financial results, have exceeded our expectations. We anticipate strong continued growth for Zelsuvmi in 2026 and with the capital raised with the issuance of the convertibles notes in November 2025 and the term debt issued in January 2026, we believe that our cash balance provides the runway to execute on our business plan. In addition, the recent acquisition of Xepi and Xeglyze have added two highly complementary products to our portfolio. FDA-approved Xepi and Xeglyze each treat infectious skin conditions primarily impacting children, which aligns with the same target market as Zelsuvmi . This presents our sales reps and Pelthos with a synergistic opportunity to increase revenue by leveraging our current commercial relationships and infrastructure with de minimis additional SG&A. We believe we are well-positioned to capitalize on the large addressable markets and unmet needs presented by these three products and have the commercial infrastructure and experience to continue to grow Zelsuvmi and launch and grow Xepi and Xeglyze."
